Protocol Title: A phase IIIb, open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecaprevir (300mg)/pibrentasvir (120mg) in chronic HCV treatment naïve patients without cirrhosis
Protocol No: VHCRP1701

Pharmacy Signature and Study Responsibilities Log

Site Name: _____ **Site Code:** _____ **Principal Investigator:** _____

Name of Site Personnel *(first and last names)*	**Signature***	**Initials**	**Start Date** *(dd/mmm/yyyy)*	**End Date** *(dd/mmm/yyyy)*	**Role**	**Responsibility Code(s)^** *(indicate codes using codes in attached key)*

^Study Responsibility Codes

1. Monitor investigational product (IP) receipt, stock and storage condition 2. IP dispensation 3. IP accountability 4. IP destruction 5. Maintenance of Investigator Site File (Pharmacy File)	6. Other (specify)_____ 7. Other (specify)_____ 8. Other (specify)_____

**CV must be current within ≤3 years and a copy must be available within the Investigator Site File and sent to Kirby Institute.**
***** **By signing the SMART-C Site Signature and Study Responsibilities Log, you agree that your contact details may be disclosed to AbbVie Inc.**